Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 48-Week, Multicentre, Multinational, Randomized, Double-Blind, 2-Arm Parallel Group, Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-Dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics > or = 18 Years of Age

Trial Profile

A 48-Week, Multicentre, Multinational, Randomized, Double-Blind, 2-Arm Parallel Group, Comparing the Efficacy of Foster for Maintenance and Reliever Versus Fixed-Dose Foster for Maintenance Plus Salbutamol as Reliever in Asthmatics > or = 18 Years of Age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Salbutamol
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Chiesi Farmaceutici

Most Recent Events

  • 21 Apr 2012 Planned number of patients changed from 2404 to 2482 as reported by European Clinical Trials Database.
  • 21 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.
  • 16 Feb 2012 Actual patient number is 2079 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top